Gonadorelin
Reproductive Health, Hormone Balance
In short
- Synthetic gonadotropin-releasing hormone (GnRH), identical to the endogenous decapeptide.
- Was FDA-approved as a diagnostic agent for evaluating pituitary gonadotropin function.
- Extremely short half-life — 2 to 10 minutes — which is the central practical problem with it.
- Increasingly used in place of HCG for testicular maintenance, though the pharmacological rationale for that substitution is weaker than commonly assumed.
- Continuous GnRH stimulation DOWNREGULATES the axis rather than stimulating it, which is the opposite of the intended effect.
Structure
How it works
Gonadorelin is identical to natural GnRH. It acts on pituitary gonadotrophs to stimulate release of LH and FSH, which in turn stimulate the gonads.
The critical property is that GnRH signalling is pulsatile by design. Physiological release occurs in discrete pulses every 60–120 minutes, and the pituitary responds to that pattern. Continuous or too-frequent stimulation causes receptor downregulation and suppression — this is precisely how GnRH agonists like leuprolide achieve chemical castration.
So the same molecule stimulates or suppresses depending entirely on the timing of administration, which makes dosing pattern more consequential here than dose.
What the research shows
As a diagnostic agent for pituitary function: established and was approved on that basis.
Pulsatile GnRH via infusion pump is an established treatment for hypogonadotropic hypogonadism and can restore fertility — but this requires a pump delivering pulses every 90 minutes or so.
For testicular maintenance during testosterone therapy, gonadorelin is now widely prescribed by telehealth clinics. Controlled evidence for this specific use, at the doses and frequencies used, is thin. HCG has considerably more supporting data.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Human — approved diagnostic use, pituitary evaluation | 100 µg as a single dose | subcutaneous or intravenous | PubMed |
| Human — pulsatile therapy for hypogonadotropic hypogonadism | 5–20 µg per pulse, every 90–120 minutes via pump | subcutaneous pump | PubMed |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly prescribed alongside TRT | 100–200 µg once or twice daily | subcutaneous |
The pharmacological issue is timing, not amount. Physiological GnRH is pulsatile every 60-120 minutes; therapeutic use for fertility requires a pump to reproduce that. Once- or twice-daily injection reproduces neither the physiological pattern nor the continuous-suppression pattern, and what it actually achieves for testicular maintenance is not well characterised.
Handling and storage
Supplied as a lyophilised powder requiring reconstitution with bacteriostatic water. The powder is comparatively stable; once reconstituted it is refrigerated and used within weeks. Track the date you reconstitute each vial — the Inventory section does this, and it is the difference between knowing a vial is three weeks old and guessing.
Subcutaneous injection. The 2-10 minute half-life means any given injection produces a very brief pulse.
Pulsatile pump delivery is the route with genuine evidence for fertility indications and is a clinical intervention rather than a self-administered one.
Side effects
Generally well tolerated. Reported: injection-site reactions, headache, flushing, nausea, and abdominal discomfort.
The approved diagnostic use has a real safety record at single doses.
The theoretical concern with frequent non-pulsatile dosing is pituitary desensitisation — the mechanism GnRH agonists exploit deliberately. Whether typical community dosing frequencies approach this has not been studied.
Combinations
Used alongside testosterone replacement as an alternative to HCG. HCG acts directly at the testis, gonadorelin acts upstream at the pituitary — which means gonadorelin requires an intact and responsive pituitary to do anything, while HCG does not.
That difference matters: in someone whose pituitary is suppressed by exogenous testosterone, the upstream signal has less to work with.
Research status
Established endocrinology with approved diagnostic use and genuine evidence for pulsatile therapy in hypogonadotropic hypogonadism.
The current widespread use for TRT-adjacent testicular maintenance substantially outpaces the evidence supporting it at those dosing patterns.
Legal status
Was FDA-approved as a diagnostic agent; availability of branded products has changed over time. Widely supplied through compounding pharmacies by prescription, particularly via telehealth TRT clinics.
WADA status
PROHIBITED for male athletes at all times under WADA class S2, which covers gonadotropin releasing factors. Explicitly within the named category.
Conclusion
Gonadorelin is real GnRH with real approved uses, now widely prescribed for a purpose where HCG has better evidence.
The thing most discussion misses is that GnRH biology is fundamentally about pulse timing, not dose. A twice-daily injection is neither physiological pulsatility nor deliberate suppression, and what it accomplishes in between is not well established.
Sources
Track your own Gonadorelin protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.